Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases

Bone Marrow Transplantation

Volumn 39, Issue 7, 2007, Pages 383-388

  Ringden O ^a   Remberger, M ^a   Svenberg, P ^a   Svahn, B M ^a   Dahllof G ^a   Gustafsson, B ^a   Hassan, Z ^a   Omazic, B ^a   Uzunel, M ^a   Aschan, J ^a   Barkholt, L ^a   Winiarski, J ^a   Ljungman, P ^a   Mattsson, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BILIRUBIN; BUSULFAN; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUDARABINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR1 ANTIGEN; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGRANULOCYTOSIS; ALOPECIA; APLASTIC ANEMIA; ARTICLE; BACTEREMIA; BILIRUBIN BLOOD LEVEL; CHILD; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC GRANULOMATOUS DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DONOR SELECTION; DRUG FATALITY; DRUG FEVER; ENGRAFTMENT; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIC PROTOPORPHYRIA; FANCONI ANEMIA; FEMALE; GRAFT FAILURE; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HISTIOCYTOSIS X; HLA MATCHING; HUMAN; HURLER SYNDROME; INFANT; INTERMETHOD COMPARISON; KIDNEY FUNCTION; LEUKODYSTROPHY; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; MYCOSIS; MYELOABLATIVE CONDITIONING; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PNEUMONIA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SICKLE CELL ANEMIA; SIDE EFFECT; SPIROMETRY; SURVIVAL RATE; THALASSEMIA MAJOR; THROMBOCYTE TRANSFUSION; WHOLE BODY RADIATION; WISKOTT ALDRICH SYNDROME;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINOPATHIES; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; MALE; MIDDLE AGED; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 33947684947     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705602     Document Type: Article

References (32)

1. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
2. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
3. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
4. O'Reilly RJ, Kapoor N, Kirkpatrick D, Flomenberg N, Pollack MS, Dupont B et al. Transplantation of hematopoietic cells for lethal congenital immunodeficiencies. Birth Defects Orig Artic Ser 1983; 19: 129-137.
5. Peters C, Steward CG. Hematopoietic cell transplantation for inherited metabolic diseases: An overview of outcomes and practice guidelines. Bone Marrow Transplant 2003; 31: 229-239.
6. Storb R, Etzioni R, Anasetti C, Appelbaum FR, Buckner CD, Bensinger W et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941-949.
7. Lucarelli G, Clift RA, Galimberti M, Polchi P, Angelucci E, Baronciani D et al. Marrow transplantation for patients with thalassemia: Results in class 3 patients. Blood 1996; 87: 2082-2088.
8. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620-1629.
9. Bitan M, Or R, Shapira MY, Aker M, Resnick IB, Ackerstein A et al. Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors. Biol Blood Marrow Transplant 2006; 12: 712-718.
10. Del Toro G, Satwani P, Harrison L, Cheung YK, Brigid BM, George D et al. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant 2004; 33: 613-622.
11. Fukano R, Nagatoshi Y, Shinkoda Y, Saito Y, Takahashi D, Hatanaka M et al. Unrelated bone marrow transplantation using a reduced-intensity conditioning regimen for the treatment of Kostmann syndrome. Bone Marrow Transplant 2006; 38: 635-636.
12. Horwitz ME, Barrett AJ, Brown MR, Carter CS, Childs R, Gallin JI et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 2001; 344: 881-888.
13. Jacobsohn DA, Duerst R, Tse W, Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 2004; 364: 156-162.
14. Kikuta A, Ito M, Mochizuki K, Akaihata M, Nemoto K, Sano H et al. Nonmyeloablative stem cell transplantation for nonmalignant diseases in children with severe organ dysfunction. Bone Marrow Transplant 2006; 38: 665-669.
15. Rao K, Amrolia PJ, Jones A, Cale CM, Naik P, King D et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005; 105: 879-885.
16. Cesaro S. Will a reduced-toxicity conditioning regimen improve the results of stem cell transplantation in metabolic disease? Bone Marrow Transplant 2006; 37: 615.
17. Ringden O, Svenberg P, Le Blanc K, Mattsson J, Remberger M. Myeloablative conditioning for hematopoietic stem-cell transplantation in patients with non-malignant diseases. Bone Marrow Transplant 2006; 38: 321-322.
18. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2h: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225-235.
19. Ringden O, Remberger M, Runde V, Bornhauser M, Blau IW, Basara N et al. Peripheral blood stem cell transplantation from unrelated donors: A comparison with marrow transplantation. Blood 1999; 94: 455-464.
20. Aker M, Varadi G, Slavin S, Nagler A. Fludarabine-based protocol for human umbilical cord blood transplantation in children with Fanconi anemia. J Pediatr Hematol Oncol 1999; 21: 237-239.
21. Shaw PJ, Hugh-Jones K, Hobbs JR, Downie CJ, Barnes R. Busulphan and cyclophosphamide cause little early toxicity during displacement bone marrow transplantation in fifty children. Bone Marrow Transplant 1986; 1: 193-200.
22. Storb R, Deeg HJ, Fisher L, Appelbaum F, Buckner CD, Bensinger W et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: Long-term follow-up of three controlled trials. Blood 1988; 71: 293-298.
23. Svahn BM, Remberger M, Myrback KE, Holmberg K, Eriksson B, Hentschke P et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood, 2002; 100: 4317-4324.
24. Mattsson J, Uzunel M, Tammik L, Aschan J, Ringden O. Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia 2001; 15: 1976-1985.
25. Ljungman P, Aschan J, Lewensohn-Fuchs I, Carlens S, Larsson K, Lonnqvist B et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998; 66: 1330-1334.
26. Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977-1983.
27. Ringden O, Remberger M, Ruutu T, Nikoskelainen J, Volin L, Vindelov L et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 1999; 93: 2196-2201.
28. Remberger M, Storer B, Ringden O, Anasetti C. Association between pretransplant thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002; 29: 391-397.
29. Ringden O, Barrett AJ, Zhang MJ, Loberiza FR, Bolwell BJ, Cairo MS et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol 2003; 121: 874-885.
30. Ringden O, Remberger M, Svahn BM, Barkholt L, Mattsson J, Aschan J et al. Allogeneic hematopoietic stem cell transplantation for inherited disorders: Experience in a single center. Transplantation 2006; 81: 718-725.
31. Gluckman E, Pasquini R, Rocha V, Harris R, Locatelli F. Results of unrelated cord blood transplants in Fanconi anemia. Blood 2003; 102, abstract 859.
32. Garwicz S, Anderson H, Olsen JH, Dollner H, Hertz H, Jonmundsson G et al. Second malignant neoplasms after cancer in childhood and adolescence: A population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries. Int J Cancer 2000; 88: 672-678.